Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it ...

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to ...

The startup has a broad global development program underway — and the support of more than 20 investment firms — for a ...